CM
ALNY icon

Capula Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Capula Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.97M Buy
13,203
+88
+0.7% +$26.5K 0.01% 194
2026
Q1 		$4.34M Sell
13,115
-66
-0.5% -$22.5K 0.03% 140
2025
Q4 		$5.24M Buy
13,181
+6,293
+91% +$2.79M 0.03% 149
2025
Q3 		$3.14M Buy
+6,888
New +$2.8M 0.02% 197
2024
Q1 		– Sell
-5,270
Closed -$1.01M – 469
2023
Q4 		$1.01M Buy
+5,270
New +$898K 0.04% 100

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capula Management's ALNY Position: Q2 2026 in Review

Capula Management increased its Alnylam Pharmaceuticals (ALNY) stake by 0.67% in Q2 2026, buying an estimated $26.5K and bringing the position to 13,203 shares worth $3.97M. The position accounts for 0.01% of the portfolio, ranked #194.

Capula Management first reported a position in ALNY in Q4 2023 and has held it in 5 quarters since. The position peaked at $5.24M in Q4 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Capula Management held 13,203 shares of Alnylam Pharmaceuticals worth $3.97M as of Q2 2026.
  • Capula Management bought 88 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $26.5K.
  • Alnylam Pharmaceuticals made up 0.01% of Capula Management's portfolio in Q2 2026, its #194 holding.
  • Capula Management first reported a position in Alnylam Pharmaceuticals in Q4 2023 and has held it in 5 quarters since.
  • Capula Management's Alnylam Pharmaceuticals position peaked at $5.24M in Q4 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Capula Management's 13F filing for Q2 2026, filed 14 Aug 2026.